Justification for the Nomination

Professor Chiranjib Chakraborty is the nominee for the award in the category of Medical Sciences-Basic Research from Sun Pharma Science Foundation.

Professor Chakraborty is an eminent Scholar and researcher. He is working as a Professor at the School of Life Science and Biotechnology, Adamas University, Kolkata, India and also a Visiting Professor at Hallym University, College of Medicine, South Korea. **He has been a full professor for more than ten years. Professor Chakraborty has been selected for India's highly prestigious "Tata Innovation Fellowship" for 2022-2023 from the Department of Biotechnology, Ministry of Science and Technology, Govt. of India. Dr. Chakraborty was also listed in the top 2% of Scientists of the World by Stanford University, USA/Elsevier for three consecutive years (2020, 2022, and 2022). He has more than 19 years of teaching, 27 years of research, and more than ten years of Editorial experience in reputed journals.**

His current research interests are medical bioinformatics, immunoinformatics-based vaccine development, ncRNA, especially infectious diseases, therapeutics, etc. **His research matrix is as follows:**

Publications (SCIE/Scopus): 281; Book published 5; Edited Book 2; Book Chapters: 09; h-index:53; i10 index: 146; Citation: 8889 (Google Scholar); i200 index: 7 and i100 index: 19; Scopus h-index: 44; Cumulative SCI Impact Factor: 1868.166 Average Impact Factor: 6.64; Technology developed: 12; Patent (applied): 7; Patent (granted):1 Corresponding Author (SCI & Scopus indexed):251 (Corresponding since 2003); Ph.D. guided:03 (Degree awarded); Invited talks: 19; Research Award received: 11

A brief output of his citation and brief profile can be reached at the following link:
http://scholar.google.co.in/citations?hl=en&user=3m8rwpUAAAAJ
Profile: http://community.frontiersin.org/people/ChiranjibChakraborty/18716

His group developed the world's first muti-epitopic next-generation immunoinformatics-based vaccine construct against SARS-CoV-2, published in the Journal of Medical Virology (92(6):618-631.doi: 10.1002/jmv.25736.)(Impact factor (IF)= 12.7), and the work has been cited 374 times. The technology has been granted a South Korean patent (Patent no 10-2425 492; Application Date: 27. 04. 2020. Grant Date: 21.07. 2022). Recently, they have developed an artificial intelligence (AI)-based, mutation-proof, next-generation vaccine construct against SARS-CoV-2. It was the first AI-based vaccine construct. It was published in the International Journal of Biological Macromolecules (2023, 242(Pt 2):124893.doi: 10.1016/j.ijbiomac.2023.124893.) with an IF= 8.2, and the technology was also applied for the patent. Similarly, he and his colleagues developed the world's first muti-epitopic next-generation candidate against the monkeypox virus by screening its whole genome encoded proteins published in Travel Medicine and Infectious Disease 50:102481doi: 10.1016/j.tmaid.2022.102481; IF: 12.7) and the technology was applied for the patent.

Name of the Nominator: Professor Dr. Sang-Soo Lee, M.D., Ph.D.

Designation and complete Office Address: Director, Institute For Skeletal Ageing, Room No. 3604 College of Medicine, Hallym University, Dept. of Orthopedic Surgery, College of Medicine, Hallym University, Chuncheon, Sacred Heart Hospital, Chuncheon, Gangwon-Do 200-704, South Korea

Mobile No. +82-10-9484-7744; E-mail : 123sslee@gmail.com

Signature with date:

Aug. 29, 2023.

Sang Soo Lee